false 0001231457 0001231457 2024-08-01 2024-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 1, 2024

 

 

Genelux Corporation

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-41599   77-0583529

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

2625 Townsgate Road, Suite 230

Westlake Village, California

  91361
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (805) 267-9889

 

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 per share   GNLX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On August 1, 2024, Genelux Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of June 3, 2024, the record date for the Annual Meeting (the “Record Date”), 34,351,967 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

 

A total of 22,475,719 shares of the Company’s common stock were present at the Annual Meeting in person, by virtual attendance or by proxy, which represents approximately 65.43% of the shares of the Company’s common stock outstanding as of the Record Date.

 

Proposal 1. Election of Directors.

 

The Company’s stockholders elected the persons listed below as the Class II Directors, to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results are as follows:

 

Name   Votes For   Votes Withheld   Broker Non-Votes
Mary Mirabelli   13,349,192   1,386,089   7,740,438
John Thomas, Ph.D.   9,417,742   5,317,539   7,740,438

 

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.

 

The Company’s stockholders ratified the selection of Weinberg & Company, P.A. by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
20,271,624   99,110   2,104,985   0

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Genelux Corporation
     
Date: August 6, 2024 By: /s/ Thomas Zindrick, J.D.
    Thomas Zindrick, J.D.
    President and Chief Executive Officer